Novartis Cosentyx’s first IL-17 inhibitor to receive EU approval
Cosentyx is the only biologic that can be used as first-line systemic therapy in the treatment of psoriasis and as an alternative…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Novartis
Novartis approves transfer of its OTC division to GSK for Rs 1097.3 million
Novartis has approved the sale of its OTC Division to GlaxoSmithKline Consumer for Rs 1097.3 million. It may be noted that as part…
Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
To explore making medicines and drug discovery tools with CRISPR genome editing technology
Novartis completes divestment of animal health biz to Eli Lilly for $5.4 billion
The completion of this transaction will focus Novartis on its three leading businesses of global scale: innovative…
Novartis’ Cosentyx gets Japanese approval for psoriasis, psoriatic arthritis
First interleukin-17A inhibitor to get Japanese nod for either indication
CCI approves multi-billion dollar deal between GlaxoSmithKline and Novartis
It involves acquisition of GSK's portfolio of oncology products by Novartis for $16 billion
DRL closes acquisition of Habitrol brand from Novartis
Dr Reddy’s Laboratories (DRL) has closed the acquisition of Habitrol brand (an over-the-counter nicotine replacement therapy…
FDA committee votes against Novartis’ multiple myeloma lead
FDA not bound to follow Committee's guidance its review of LBH589 NDA